2-m-tolyloxy-nicotinic acid | 54629-14-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-m-tolyloxy-nicotinic acid
• 英文别名: 2-(3-Methylphenoxy)nicotinic acid；2-(3-methylphenoxy)pyridine-3-carboxylic acid
• CAS: 54629-14-0
• 化学式: C₁₃H₁₁NO₃
• mdl: MFCD09741533
• 分子量: 229.235
• InChiKey: BLRPUKYQMPSEQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-m-tolyloxy-nicotinic acid 生成 8-methyl-5H-chromeno[2,3-b]pyridin-5-one
  参考文献：
  名称：

  Benzopyranopyridine derivatives. 1. Aminoalkyl derivatives of the azaxanthenes as bronchodilating agents

  摘要：

  The preparation of the four isomeric azaxanthones 3 and a number of their aromatic ring substituted derivatives is described. These ketones were converted into the title compounds which were examined for their biological properties. The most interesting compound in this series, the 1-methyl-4-piperidylidene derivative of 1-azaxanthene, shows the profile of an orally effective potent bronchodilating agent as well as a moderate antihistamine. Biological properties of this compound were compared to a number of antihistamines as well as known bronchodilating agents. Structure-activity relationships are also discussed.

  DOI：

  10.1021/jm00235a001
• 作为产物：
  描述：

  2-氯烟酸 、 间甲酚 在 caesium carbonate 、 copper(ll) bromide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-m-tolyloxy-nicotinic acid
  参考文献：
  名称：

  含二芳基醚结构的天然萘醌衍生物的设计、合成及除草活性

  摘要：

  光合作用系统II（PS II）是生物除草剂开发的重要目标。本研究基于指甲花松和PS II D1的结合模型，设计合成了一系列含有二芳基醚的天然萘醌衍生物。生物测定表明，大多数化合物在100 μg/mL的剂量下对马齿苋和稗草根的抑制率超过80%，并且化合物B4 、 B5和C3对双子叶和单子叶杂草表现出优于市售莠去津的除草活性。特别地，化合物B5在150g ai/ha的剂量下表现出优异的除草活性。此外，与莠去津相比，化合物B5对农作物的损害较小。分子对接研究表明，化合物B5通过多种相互作用模型（例如 π-π 堆积和氢键）与豌豆PS II D1 有效相互作用。分子动力学模拟研究和叶绿素荧光测量表明，化合物B5作用于 PS II。这是针对PS II的天然萘醌衍生物的首次报道，化合物B5可能是开发针对PS II的新型除草剂的候选分子。

  DOI：

  10.1021/acs.jafc.4c01834

文献信息

• Synthesis of 1-Azaxanthones and 1-Azathioxanthones by Yb(OTf)3/TfOH Co-Catalyzed Intramolecular Friedel-Crafts Reaction
  作者：Weike Su、Can Jin、Jie Li

  DOI：10.3987/com-10-12029

  日期：——

  Intramolecular Friedel-Crafts cyclization of phenoxypyridine acids (3a-3j) and phenythiopyridine acids (4a-4i) to form 1-azaxanthones (1a-1j) and 1-azathioxanthones (2a-2i), respectively, was efficiently promoted by Yb(OTf) 3 /TfOH as co-catalysts. And a number of substrates could be cyclized in moderate to good yields.

  Yb(OTf) 有效促进苯氧基吡啶酸 (3a-3j) 和苯硫代吡啶酸 (4a-4i) 的分子内 Friedel-Crafts 环化分别形成 1-氮杂蒽酮 (1a-1j) 和 1-氮杂噻吨酮 (2a-2i) ) 3 /TfOH 作为助催化剂。并且许多底物可以以中等至良好的产率进行环化。
• Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20050197350A1

  公开（公告）日：2005-09-08

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(I)，该化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的应用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症包括贪食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾等。
• QUINOLINE, TETRAHYDROQUINOLINE AND PYRIMIDINE DERIVATIVES AS MCH ANTAGONIST
  申请人：Taisho Pharmaceutical Co. Ltd.

  公开号：EP1464335A2

  公开（公告）日：2004-10-06

  The present invention relates to compounds of the Formula (I) wherein Q is: which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及式（I）化合物 其中 Q 为 作为 MCH 受体拮抗剂的化合物。这些组合物可用于药物组合物中，其用途包括预防或治疗改善记忆功能、睡眠和唤醒、焦虑、抑郁、情绪障碍、癫痫发作、肥胖、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗塞、暴饮暴食症（包括贪食症）、厌食症、心肌梗塞、暴食症（包括贪食症）、厌食症、精神障碍（包括躁狂抑郁症）、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、药物滥用障碍和运动障碍（包括帕金森病）、癫痫和成瘾。
• VILLANI F. J.; MANN T. A.; WEFER E. A.; HANNON J.; LARCA L. L.; LANDON M.+, J. MED. CHEM. <JMCM-AR>, 1975, 18, NO 1, 1-8
  作者：VILLANI F. J.、 MANN T. A.、 WEFER E. A.、 HANNON J.、 LARCA L. L.、 LANDON M.+

  DOI：——

  日期：——
• [EN] NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF<br/>[FR] NOUVEAUX DERIVES QUINOLINE, TETRAHYDROQUINAZOLINE ET PYRIMIDINE, PROCEDES DE TRAITEMENT EN LIAISON AVEC L'UTILISATION DE CES DERNIERS
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2004087669A1

  公开（公告）日：2004-10-14

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.